Pricing in the Market for Anticancer Drugs

David H. Howard, Peter B. Bach, Ernst R. Berndt and Rena Conti

Journal of Economic Perspectives, 2015, vol. 29, issue 1, 139-62

Abstract: In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch prices of new anticancer drugs and other drugs in the so-called "specialty" pharmaceutical market have been increasing over time and that increases are unrelated to the magnitude of the expected health benefits. In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States. We restrict attention to anticancer drugs because the use of median survival time as a primary outcome measure provides a common, objective scale for quantifying the incremental benefit of new products. We find that the average launch price of anticancer drugs, adjusted for inflation and health benefits, increased by 10 percent annually—or an average of $8,500 per year—from 1995 to 2013. We argue that the institutional features of the market for anticancer drugs enable manufacturers to set the prices of new products at or slightly above the prices of existing therapies, giving rise to an upward trend in launch prices. Government-mandated price discounts for certain classes of buyers may have also contributed to launch price increases as firms sought to offset the growth in the discount segment by setting higher prices for the remainder of the market.

JEL-codes: I11 L11 L65 (search for similar items in EconPapers)
Date: 2015
Note: DOI: 10.1257/jep.29.1.139
References: Add references at CitEc
Citations: View citations in EconPapers (41)

Downloads: (external link)
http://www.aeaweb.org/articles.php?doi=10.1257/jep.29.1.139 (application/pdf)
http://www.aeaweb.org/jep/app/2901/29010139_app.pdf (application/pdf)
http://www.aeaweb.org/jep/data/2901/29010139_data.zip (application/zip)
http://www.aeaweb.org/jep/ds/2901/29010139_ds.zip (application/zip)
Access to full text is restricted to AEA members and institutional subscribers.

Related works:
Working Paper: Pricing in the Market for Anticancer Drugs (2015)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aea:jecper:v:29:y:2015:i:1:p:139-62

Ordering information: This journal article can be ordered from
https://www.aeaweb.org/journals/subscriptions

Access Statistics for this article

Journal of Economic Perspectives is currently edited by Enrico Moretti

More articles in Journal of Economic Perspectives from American Economic Association Contact information at EDIRC.
Bibliographic data for series maintained by Michael P. Albert ().